Clinical Trials List
Protocol NumberSC291-101
NCT Number(ClinicalTrials.gov Identfier)-
Completed
2024-12-01 - 2024-12-02
Phase I
Recruiting2
-
-
Sponsor
-
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/09/09
Investigators and Locations
Co-Principal Investigator
- Wei-Ching Lin Division of Radiology
- Ming-Yu Lien Division of Hematology & Oncology
- Ching Yun Hsieh Division of Hematology & Oncology
- Ching-Chan Lin Division of Hematology & Oncology
- 鄭富銘 Division of Hematology & Oncology
- Tzu-Ting Chen Division of Hematology & Oncology
- 王幸婷 Division of Hematology & Oncology
- Chi-Ching Chen Division of Hematology & Oncology
- Che-Hung Lin Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Principal Investigator
Shang-Ju Wu
Co-Principal Investigator
- Tai-Chung Huang Division of Hematology & Oncology
- 田豐銘 Division of Hematology & Oncology
- WEI-LI MA Division of Hematology & Oncology
- Chien-Chin Lin Division of Others -
- Wen-Chien Chou Division of Others -
- Huai-Hsuan Huang Division of Hematology & Oncology
- 徐思淳 Division of Others
- Ming-Che Kuo Division of Neurology
- - - Division of Hematology & Oncology
- MING YAO Division of Hematology & Oncology
- Chieh-Lung Cheng Division of Hematology & Oncology
- YAO CHI-YUAN Division of Others -
- 施怡倫 Division of Radiology
- 劉高郎 Division of Radiology
- 袁章祖 Division of Others
- CHENG-HONG TSAI Division of Hematology & Oncology
- 李思慧 Division of Family Medicine
- 林明恩 Division of Hematology & Oncology
- 柯紀綸 Division of Nuclear Medicine
- 范淞斌 Division of Neurology
The Actual Total Number of Participants Enrolled
0 Recruiting
Study Contacts
- -
Condition/Disease
-
Objectives
-
Test Drug
-
Active Ingredient
-
Dosage Form
-
Dosage
-
Endpoints
-
Inclution Criteria
-
Exclusion Criteria
-
The Estimated Number of Participants
-
Taiwan
9 participants
-
Global
57 participants
